Tharimmune Financial Statements From 2010 to 2024

THAR Stock   2.08  0.18  7.96%   
Tharimmune financial statements provide useful quarterly and yearly information to potential Tharimmune investors about the company's current and past financial position, as well as its overall management performance and changes in financial position over time. Historical trend examination of various income statement and balance sheet accounts found on Tharimmune financial statements helps investors assess Tharimmune's valuation, profitability, and current liquidity needs. Key fundamental drivers impacting Tharimmune's valuation are summarized below:
Market Capitalization
3.4 M
Earnings Share
61.01
There are over one hundred five available fundamental trend indicators for Tharimmune, which can be analyzed over time and compared to other ratios. Investors and active traders are advised to double-check Tharimmune's current fundamental performance against the performance between 2010 and 2024 to make sure the trends are evolving in the right direction.
Check Tharimmune financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Tharimmune's main balance sheet or income statement drivers, such as Net Interest Income of 142.9 K, Interest Expense of 15.7 K or Selling General Administrative of 6.2 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 0.0758. Tharimmune financial statements analysis is a perfect complement when working with Tharimmune Valuation or Volatility modules.
  
Check out the analysis of Tharimmune Correlation against competitors.
To learn how to invest in Tharimmune Stock, please use our How to Invest in Tharimmune guide.

Tharimmune Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets11.5 M10.9 MM
Slightly volatile
Short and Long Term Debt Total1.8 M2.5 M1.3 M
Slightly volatile
Other Current Liabilities819.5 K906.5 K815.9 K
Pretty Stable
Total Current Liabilities1.8 M1.8 M1.6 M
Slightly volatile
Accounts Payable898.1 K908.6 K476.9 K
Slightly volatile
Cash11.5 M10.9 MM
Slightly volatile
Long Term Debt950.6 K888.8 K666.7 K
Slightly volatile
Cash And Short Term Investments11.5 M10.9 MM
Slightly volatile
Common Stock Shares Outstanding44.5 K87 K32.9 K
Slightly volatile
Liabilities And Stockholders Equity11.5 M10.9 MM
Slightly volatile
Other Current Assets10.5 K11 K63.1 K
Slightly volatile
Other Stockholder Equity35.5 M33.8 M6.5 M
Slightly volatile
Total Liabilities2.2 M1.8 M2.1 M
Slightly volatile
Short and Long Term Debt875.1 K1.6 M675.4 K
Slightly volatile
Total Current Assets11.5 M10.9 MM
Slightly volatile
Capital Stock9321.2 K721
Slightly volatile
Short Term Debt875.1 K1.6 M675.4 K
Slightly volatile
Common Stock1.1 K1.2 K11.3 K
Slightly volatile
Current Deferred Revenue560.8 K802.5 K420 K
Slightly volatile
Non Currrent Assets Other437.3 K492 K535.7 K
Slightly volatile

Tharimmune Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Interest Expense15.7 K16.5 K230.1 K
Slightly volatile
Selling General Administrative6.2 M5.9 M1.7 M
Slightly volatile
Other Operating Expenses4.9 M9.5 M2.4 M
Slightly volatile
Research DevelopmentM3.6 M944.9 K
Slightly volatile
Total Operating Expenses4.9 M9.5 M2.4 M
Slightly volatile
Depreciation And Amortization164.8 K152.6 K203.4 K
Slightly volatile

Tharimmune Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation703.7 K831.9 K315.3 K
Slightly volatile
Begin Period Cash Flow6.8 M6.5 M929.4 K
Slightly volatile
Total Cash From Financing Activities6.1 M11.7 M2.7 M
Slightly volatile
End Period Cash Flow11.5 M10.9 MM
Slightly volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Average Payables546.8 K890 K504.9 K
Slightly volatile
Cash Per Share13212632.9597
Slightly volatile
Income Quality0.470.78330.5063
Slightly volatile
Current Ratio6.336.03091.254
Slightly volatile
Graham Number460503385
Slightly volatile
Capex Per Share0.00.00.0
Slightly volatile
Interest Debt Per Share0.180.189640.4406
Very volatile
Debt To Assets3.814.0117.1143
Slightly volatile
Ebt Per Ebit1.280.98561.3907
Slightly volatile
Quick Ratio6.336.03091.254
Slightly volatile
Cash Ratio6.336.02481.2301
Slightly volatile
Free Cash Flow Operating Cash Flow Ratio0.80.90.98
Slightly volatile
Debt Ratio3.814.0117.1143
Slightly volatile

Tharimmune Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Market Cap625.9 K658.8 K3.9 M
Slightly volatile

Tharimmune Fundamental Market Drivers

Cash And Short Term Investments10.9 M

Tharimmune Upcoming Events

21st of March 2024
Upcoming Quarterly Report
View
27th of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of March 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Tharimmune Financial Statements

Tharimmune shareholders use historical fundamental indicators, such as revenue or net income, to determine how well the company is positioned to perform in the future. Although Tharimmune investors may analyze each financial statement separately, they are all interrelated. The changes in Tharimmune's assets and liabilities, for example, are also reflected in the revenues and expenses on on Tharimmune's income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
Last ReportedProjected for Next Year
Current Deferred Revenue802.5 K560.8 K

Pair Trading with Tharimmune

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tharimmune position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tharimmune will appreciate offsetting losses from the drop in the long position's value.

Moving against Tharimmune Stock

  0.62HCM HUTCHMED DRCPairCorr
  0.6GANX Gain TherapeuticsPairCorr
  0.59EWTX Edgewise TherapeuticsPairCorr
  0.56BCTXW BriaCell TherapeuticsPairCorr
  0.48EBS Emergent BiosolutionsPairCorr
The ability to find closely correlated positions to Tharimmune could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tharimmune when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tharimmune - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tharimmune to buy it.
The correlation of Tharimmune is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tharimmune moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tharimmune moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tharimmune can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Additional Tools for Tharimmune Stock Analysis

When running Tharimmune's price analysis, check to measure Tharimmune's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tharimmune is operating at the current time. Most of Tharimmune's value examination focuses on studying past and present price action to predict the probability of Tharimmune's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tharimmune's price. Additionally, you may evaluate how the addition of Tharimmune to your portfolios can decrease your overall portfolio volatility.